Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Flat Capital AB (publ) in connection with its listing on Nasdaq First North Growth Market
Mandate

Vinge has advised Flat Capital AB (publ) in connection with its listing on Nasdaq First North Growth Market

October 20, 2021 Capital Markets and Public M&A

Vinge has advised Flat Capital AB (publ) (“Flat Capital” or the “Company”) in connection with its listing on Nasdaq First North Growth Market. The prospectus was published on 29 September 2021 and the first day of trading on Nasdaq First North Growth Market was 20 October 2021.

Flat Capital is an investment company founded by Nina and Sebastian Siemiatkowski that focuses on companies with prominent entrepreneurs in leading positions. The company aims to contribute long-term capital to entrepreneur-led companies that may otherwise be dependent on investors with shorter time horizons. The largest investments are Klarna Holding AB, Budbee AB and True Software Scandinavia AB (Truecaller).


Vinge’s team consisted of Jesper Schönbeck, Joel Wahlberg, Anna Grigorian and Anna Svensson.

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025